Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Systematic Review and Meta-Analysis of the Association Between the Use of Sglt2 Inhibitors and Hepatocellular Carcinoma Publisher



Shabani E1 ; Heidari SM2 ; Roozitalab M3 ; Zarei H4 ; Mirshekari A5 ; Ebrahimi S6 ; Doshantapeh AG7 ; Vatankhah SA8 ; Dehghanighorbi M9
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Pediatric Department, Mashhad University of Medical Sciences, Mashhad, Iran
  3. 3. Department of Operation Room, School of Paramedical, Yasuj University of Medical Science, Yasuj, Iran
  4. 4. Department of Anesthesiology, Bu-Ali Sina Hospital, Kurdistan University of Medical Sciences, Sanandaj, Iran
  5. 5. Department of Gastroenterology and Hepatology, School of Medicine, Amir al Momenin Hospital, Zabol University of Medical Science, Zabol, Iran
  6. 6. Department of Radio-Oncology, School of Medicine, Shahid Beheshti University of Medical Science, Tehran, Iran
  7. 7. Department of Hematology-Medical Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  8. 8. Persian Gulf Hospital, Social Security Organization, Bandar Abbas, Iran
  9. 9. Hematology-Oncology Department, Imam Hossein Educational Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Immunopathologia Persa Published:2025


Abstract

Introduction: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are increasingly recognized for their potential role beyond glycemic control, particularly in the context of hepatocellular carcinoma (HCC). This systematic review and meta-analysis aims to evaluate the association between SGLT2 inhibitor use and the incidence or prognosis of HCC, drawing on emerging evidence that suggests these agents may improve liver function and reduce cancer cell proliferation. Materials and Methods: This investigation was executed in accordance with the PRISMA guidelines, employing a systematic review and meta-analysis methodology. In this investigation, the databases ProQuest, PubMed, Embase, Web of Science, Cochrane, as well as the Google Scholar search engine, were scrutinized until August 25, 2024. The analysis of the data was conducted utilizing STATA 14 software, with the threshold for statistical significance established at P<0.05. Results: In seven reviewed studies, 422,174 individuals were evaluated, and the results indicated that there was no significant association between the use of SGLT2i and HCC (HR: 0.65; 95% CI: 0.41, 1.01). However, SGLT2i use reduced the risk of HCC by 36% compared to dipeptidyl peptidase-4 inhibitors (DPP4) and by 73% compared to beta blockers. The use of SGLT2i decreased the risk of HCC in women (56%) and men (55%). In Asia, there was no significant relationship between SGLT2i use and HCC (HR: 0.57; 95% CI: 0.27, 1.16), while in Europe and the Americas, it reduced the risk of HCC by 22% and 32%, respectively. Among patients aged 50 to 59 years, there was no significant association between SGLT2i use and HCC (HR: 0.89; 95% CI: 0.63, 1.25), but in those aged 60 to 69 years, SGLT2i use resulted in a 62% reduction in HCC risk. There was no significant association between SGLT2i use and liver cirrhosis (HR: 0.98; 95% CI: 0.76, 1.26). Conclusion: In conclusion, while the overall analysis reveals no significant association between SGLT2 inhibitor use and HCC, the findings suggest a noteworthy reduction in HCC risk compared to other treatments, particularly in older adults and across different regions. These results highlight the potential benefits of SGLT2 inhibitors in mitigating HCC risk, warranting further investigation to clarify their role in liver cancer prevention. © 2025 The Author(s)
Other Related Docs
30. Sglt2 Inhibitors and Ampk: The Road to Cellular Housekeeping?, Cell Biochemistry and Function (2024)